Amy S Chappell

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects
    S S Jhee
    California Clinical Trials Medical Group, Inc, 1509 Wilson Terrace, 55 Wing Main Floor, Glendale, CA 91206 4007, USA
    J Clin Pharmacol 46:424-32. 2006
  2. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
  3. pmc Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
    Laurence A Bradley
    Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama 35294, USA
    Arthritis Res Ther 12:R141. 2010
  4. ncbi request reprint A crossover, add-on trial of talampanel in patients with refractory partial seizures
    A S Chappell
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neurology 58:1680-2. 2002
  5. doi request reprint A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia
    Amy S Chappell
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Clin J Pain 25:365-75. 2009
  6. ncbi request reprint AMPA potentiator treatment of cognitive deficits in Alzheimer disease
    A S Chappell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neurology 68:1008-12. 2007
  7. doi request reprint Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pain Med 11:648-57. 2010
  8. doi request reprint A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Pract 11:33-41. 2011
  9. doi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
  10. ncbi request reprint An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007

Detail Information

Publications15

  1. ncbi request reprint Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects
    S S Jhee
    California Clinical Trials Medical Group, Inc, 1509 Wilson Terrace, 55 Wing Main Floor, Glendale, CA 91206 4007, USA
    J Clin Pharmacol 46:424-32. 2006
    ..LY450108 and LY451395 1 mg and 5 mg were measured in the CSF. Single and multiple oral doses of LY450108 and LY451395 were determined to be safe and well tolerated in healthy subjects...
  2. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
    ..Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo)...
  3. pmc Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
    Laurence A Bradley
    Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama 35294, USA
    Arthritis Res Ther 12:R141. 2010
    ..This study tested the hypothesis that baseline ratings of fatigue/tiredness would be negatively associated with the efficacy of duloxetine on measures of pain and functional ability in patients with fibromyalgia...
  4. ncbi request reprint A crossover, add-on trial of talampanel in patients with refractory partial seizures
    A S Chappell
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neurology 58:1680-2. 2002
    ..001) with a median seizure reduction of 21%. Eighty percent of patients had fewer seizures on talampanel than on placebo. Dizziness (52%) and ataxia (26%) were the only significant adverse events...
  5. doi request reprint A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia
    Amy S Chappell
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Clin J Pain 25:365-75. 2009
    ..Evaluate the efficacy and safety of duloxetine at doses up to 120 mg once daily in patients with fibromyalgia...
  6. ncbi request reprint AMPA potentiator treatment of cognitive deficits in Alzheimer disease
    A S Chappell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neurology 68:1008-12. 2007
    ..To investigate the efficacy and safety of the positive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid modulator LY451395 in patients with mild to moderate Alzheimer disease (AD) (Mini-Mental State Examination scores 14 to 26)...
  7. doi request reprint Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study
    Vladimir Skljarevski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pain Med 11:648-57. 2010
    ..To assess the maintenance of the effect of duloxetine in the treatment of chronic low back pain...
  8. doi request reprint A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Pract 11:33-41. 2011
    ..To evaluate the efficacy and safety of duloxetine in the treatment of chronic pain due to osteoarthritis of the knee...
  9. doi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
    ..This was a randomized, double-blind, placebo-controlled clinical trial...
  10. ncbi request reprint An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007
    ..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)...
  11. doi request reprint Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Vladimir Skljarevski
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Diabetes Metab Res Rev 25:623-31. 2009
    ..To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP)...
  12. doi request reprint Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis
    Madelaine M Wohlreich
    correspondence and M D, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4103, Indianapolis, IN 46285, USA
    Psychosomatics 50:402-12. 2009
    ....
  13. doi request reprint A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis
    Robert M Pascuzzi
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Amyotroph Lateral Scler 11:266-71. 2010
    ..These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS...
  14. pmc A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Int J Gen Med 1:91-102. 2009
    ..Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment...
  15. ncbi request reprint LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine
    C N Sang
    Massachusetts General Hospital, Boston, USA
    Cephalalgia 24:596-602. 2004
    ..Larger trials are needed to further test the hypothesis...